Clinical Trials Logo

Filter by:
NCT ID: NCT05356702 Active, not recruiting - Alzheimer Disease Clinical Trials

The Brain Health Study: A Pragmatic, Patient-Centered Trial

Start date: June 29, 2022
Phase: N/A
Study type: Interventional

The eRADAR Brain Health Study seeks to refine and test a novel, low-cost strategy for increasing dementia detection within primary care.

NCT ID: NCT05356637 Active, not recruiting - Osteoarthritis, Hip Clinical Trials

Bipolar Sealer for Reduction of Blood Loss in Anterior Total Hip Arthroplasties

Start date: April 29, 2022
Phase: N/A
Study type: Interventional

The overall objectives and purpose of this study is to show that the Smith and Nephew Werewolf Fastseal 6.0 Bipolar Sealer is an effective tool to aide the surgical team in providing significant hemostasis during anterior total hip arthroplasty which would subsequently improve patient outcomes.

NCT ID: NCT05356130 Active, not recruiting - Depression Clinical Trials

Bright Start Study

Start date: February 17, 2022
Phase: N/A
Study type: Interventional

The Bright Start study is a randomized trial to compare three approaches, or "arms", for delivering Bright Light Therapy (BLT) to real-world patients. Arm 1 participants will receive Kaiser Permanente (KP) treatment as usual (TAU) with no BLT assistance. Arm 2 participants will receive brief written educational material on BLT but no phone coaching. Arm 3 participants will receive written educational material and phone coaching assistance for BLT initiation and adherence. This pilot will prepare for a future, fully powered effectiveness trial and is not powered for hypothesis testing. Therefore, the investigators do not expect between-condition comparisons to yield significant differences. The investigators will conduct analyses similar to those that would be used in a subsequent fully powered trial of the same design. These pilot study analyses posit that (a) Arms 2+3 are superior to Arm 1 in PHQ-9 continuous depression response; and (b) Arm 3 is superior to Arm 2 in PHQ-9 continuous depression response. The investigators will also conduct exploratory analyses to prepare for a future fully powered trial.

NCT ID: NCT05355090 Active, not recruiting - Type 2 Diabetes Clinical Trials

Daily Protein Pacing Effects on HbA1c in Type 2 Diabetics

Start date: April 6, 2022
Phase: N/A
Study type: Interventional

This study will examine the effects of protein (whey) supplementation added to the normal diet of pre-diabetes or diagnosed type 2 diabetes mellitus (T2DM) men and women on plasma glycated hemoglobin (HbA1c) and total body fat levels. Specifically, this study will directly quantify the impact of 3x/day timed ingestion of supplemental whey protein (20 grams of 80 calories per serving) added to the normal diet of free-living pre-diabetic or T2DM men and women over an 8-week study period on the major diagnostic outcome of pre-diabetic and T2DM (HbA1c levels) and total body fat levels. This study will quantify changes in HbA1C and total body fat levels in 24 pre-diabetics or T2DM participants.

NCT ID: NCT05353998 Active, not recruiting - Clinical trials for Obstructive Sleep Apnea

Efficacy of Clinical Decision Support and Sleep Navigation (Sleep PASS)

Start date: August 1, 2022
Phase: N/A
Study type: Interventional

The purpose of the study is to examine the feasibility, acceptability, and initial outcomes of clinical decision support (CDS) and a Sleep Navigation program to enhance primary to specialty care management of pediatric sleep-disordered breathing (SDB).

NCT ID: NCT05353985 Active, not recruiting - Celiac Disease Clinical Trials

A Study of TAK-062 in Treatment of Active Celiac Disease in Participants Attempting a Gluten-Free Diet

Start date: June 30, 2022
Phase: Phase 2
Study type: Interventional

The main aim is to see how TAK-062 works to reduce celiac-related symptoms and improve small intestinal damage due to gluten exposure, in participants with celiac disease (CeD) attempting to maintain a gluten-free diet (GFD) in treated participants versus placebo controls.

NCT ID: NCT05353842 Active, not recruiting - Clinical trials for Spinal Cord Injuries

Scale Up of Project Workout on Wheels Internet Intervention (WOWii)

WOWii
Start date: January 2, 2022
Phase: N/A
Study type: Interventional

This study is designed is to test the feasibility, fidelity, and effectiveness of scaling up an evidence- and theory-based virtually delivered physical activity intervention (WOWii) for individuals living with chronic SCI for delivery through other rehabilitation settings. The study outcomes address (1) feasibility based on participant enrollment, retention, and program engagement; (2) fidelity of intervention delivery; and (3) program effectiveness based on subjective and objective exercise data, and participant exercise perceptions regarding self-efficacy and barriers.

NCT ID: NCT05353790 Active, not recruiting - Cognitive Change Clinical Trials

Dietary Exchanges With Avocado and Mango in Pre-diabetes

AVMa
Start date: October 11, 2021
Phase: N/A
Study type: Interventional

The research is designed as a randomized, 2-arm, parallel, controlled, human clinical trial to investigate the effects of avocado and mango consumption for 8 weeks on indices of macro- and micro- vascular function in individuals with prediabetes. FMD of the brachial artery, pulse wave velocity (PWV), central blood pressure (cBP), and Optical Coherence Tomography Angiography (OCTA) of the eye will be used for vascular assessments. The research plan will also explore cognitive and kidney function benefits of regular avocado and mango intake using specified cognitive tasks and kidney function biomarkers

NCT ID: NCT05352828 Active, not recruiting - Clinical trials for Classical Hodgkin Lymphoma

Autologous CD30.CAR-T in Combination With Nivolumab in cHL Patients After Failure of Frontline Therapy

ACTION
Start date: July 25, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1b, multicenter, open-label, single arm study to evaluate the safety and efficacy of the combination therapy, CD30.CAR-T and the programmed cell death protein-1 (PD-1) checkpoint inhibitor, nivolumab, in patients aged 12 years of age and above with relapsed or refractory classical Hodgkin lymphoma (cHL) following failure of standard frontline therapy.

NCT ID: NCT05352763 Active, not recruiting - Alzheimer's Disease Clinical Trials

Open-Label Extension of the PTI-125-04 Study in Mild-to-Moderate Alzheimer's Disease

Start date: May 12, 2022
Phase: Phase 2
Study type: Interventional

This is a 96-week extension study of open-label simufilam 100 mg b.i.d. for mild-to-moderate Alzheimer's disease subjects who completed the Phase 2 study, PTI-125-04. The study will evaluate safety and long-term treatment. Safety will be assessed by AE monitoring, clinical labs, urinalysis, vital signs, ECGs, and C-SSRS.